<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788864</url>
  </required_header>
  <id_info>
    <org_study_id>17MA</org_study_id>
    <nct_id>NCT02788864</nct_id>
  </id_info>
  <brief_title>Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers</brief_title>
  <acronym>PREMAL</acronym>
  <official_title>A Randomized, Placebo-controlled, Double-blind Trial Using Dihydroartemisinine+Piperaquine (DP) to Protect Forest Workers From Malaria in Bu Gia Map National Park</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford University Clinical Research Unit, Vietnam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Binh Phuoc Malaria Control Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bu Gia Map National Park, Binh Phuoc Province, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxford University Clinical Research Unit, Vietnam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess if the antimalarial drugs Dihydroartemisinine +
      Piperaquine (DP) are effective in preventing malaria infection for forest ranger
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the protective effect of 3-day DP regimen for forest rangers working for long-term
      in forest where malaria transmission is intense, all eligible forest rangers will be treated
      with a full course of DP + primaquine to eradicate all parasites which may survive in their
      blood while staying in non- malaria transmission areas.

      Just before returning back to the forest participants will be randomized to receive either
      Arterakine (dihydroartemisinine (DHA)/piperaquine) (intervention arm) or placebo (control
      arm). Participants will be assessed for parasitemia before and after the forest trip with
      high volume, ultrasensitive, PCR (HVUqPCR). The minimum time span between two forest trips
      should be 20 days so participants could complete the 14 day primaquine course and the
      Arterakine (dihydroartemisinine (DHA)/piperaquine).

      There is no limit in the duration between trips. Participants are tested for P.falciparum,
      P.vivax infection before they return to the forest.

      Each participant will be visited 2 weeks or later after returning home from the forest and
      examined. The rationale for the added two weeks is to detect blood stages of infections,
      which may have been inoculated towards the end of the forest visit.

      If found to be sick, the patient will be treated according to government treatment
      guidelines. A 4ml venous blood sample will be obtained for Hb and HVUSqPCR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2016</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of study subjects with any malaria parasitaemia (P.falciparum, mixed parasitaemia of P.falciparum and P.vivax) and the incidence rate of symptomatic malaria</measure>
    <time_frame>at 2 weeks after coming back from the forest</time_frame>
    <description>The primary endpoints are the proportion of study subjects with any malaria parasitaemia (P.falciparum, mixed parasitaemia of P.falciparum and P.vivax) at 2 weeks after coming back from the forest assessed by high volume, ultrasensitive PCR (HVUSqPCR) and the incidence rate of symptomatic malaria (P.falciparum, mixed P.falciparum + P.vivax) during the two week follow-up period as assessed by the study doctor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of different anopheles species amongst all captured mosquito anopheles</measure>
    <time_frame>1 month</time_frame>
    <description>The proportion of different anopheles species amongst all captured mosquito anopheles as identified by morphology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of sporozoite-carrying mosquitoes (any parasite, P.falciparum, mixed P.falciparum and P.vivax)</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of sporozoite-carrying mosquitoes (any parasite, P.falciparum, mixed P.falciparum and P.vivax) as assessed by PCR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Arterakine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinin; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (visually matched to Arterakine for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arterakine (DHA/piperaquine)</intervention_name>
    <description>Stage 1: Parasite Clearance
Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days
Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days
Stage 2: Forest trip
• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)</description>
    <arm_group_label>Arterakine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stage 1: Parasite Clearance
Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days
Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days
Stage 2: Forest trip
• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent

          2. Male, over or equal to18 years of age

          3. Able and willing to comply with the study requirements and follow-up

        Exclusion Criteria:

          1. Inability to tolerate oral treatment

          2. Previous episode of haemolysis or severe haemoglobinuria following primaquine

          3. Glucose-6-phosphate dehydrogenase (G6PD) deficient with Hb &lt; 9 g/dL *

          4. Known hypersensitivity or allergy to any study drugs * If the participant with G6PD
             deficient gets malaria, primaquine would be used as recommended by World Health
             Organization (WHO) (once a week for 8 weeks) in combination with 3 days of
             chloroquine.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hung Son Do, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bu Gia Map Commune Health Station</name>
      <address>
        <city>Binh Phuoc</city>
        <zip>830000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Thanh PV, Van Hong N, Van Van N, Van Malderen C, Obsomer V, Rosanas-Urgell A, Grietens KP, Xa NX, Bancone G, Chowwiwat N, Duong TT, D'Alessandro U, Speybroeck N, Erhart A. Epidemiology of forest malaria in Central Vietnam: the hidden parasite reservoir. Malar J. 2015 Feb 19;14:86. doi: 10.1186/s12936-015-0601-y.</citation>
    <PMID>25880664</PMID>
  </reference>
  <reference>
    <citation>Parker DM, Carrara VI, Pukrittayakamee S, McGready R, Nosten FH. Malaria ecology along the Thailand-Myanmar border. Malar J. 2015 Oct 5;14:388. doi: 10.1186/s12936-015-0921-y.</citation>
    <PMID>26437860</PMID>
  </reference>
  <reference>
    <citation>Abe T, Honda S, Nakazawa S, Tuong TD, Thieu NQ, Hung le X, Thuan le K, Moji K, Takagi M, Yamamoto T. Risk factors for malaria infection among ethnic minorities in Binh Phuoc, Vietnam. Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):18-29.</citation>
    <PMID>19323029</PMID>
  </reference>
  <reference>
    <citation>Sanh NH, Van Dung N, Thanh NX, Trung TN, Van Co T, Cooper RD. Forest malaria in central Vietnam. Am J Trop Med Hyg. 2008 Nov;79(5):652-4.</citation>
    <PMID>18981498</PMID>
  </reference>
  <reference>
    <citation>Erhart A, Ngo DT, Phan VK, Ta TT, Van Overmeir C, Speybroeck N, Obsomer V, Le XH, Le KT, Coosemans M, D'alessandro U. Epidemiology of forest malaria in central Vietnam: a large scale cross-sectional survey. Malar J. 2005 Dec 8;4:58.</citation>
    <PMID>16336671</PMID>
  </reference>
  <reference>
    <citation>Erhart A, Thang ND, Hung NQ, Toi le V, Hung le X, Tuy TQ, Cong le D, Speybroeck N, Coosemans M, D'Alessandro U. Forest malaria in Vietnam: a challenge for control. Am J Trop Med Hyg. 2004 Feb;70(2):110-8.</citation>
    <PMID>14993619</PMID>
  </reference>
  <reference>
    <citation>Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, Suangkanarat P, Jeeyapant A, Vihokhern B, Wongsaen K, Van Hue D, Dong le T, Nguyen TU, Lubell Y, von Seidlein L, Dhorda M, Promnarate C, Snounou G, Malleret B, Rénia L, Keereecharoen L, Singhasivanon P, Sirithiranont P, Chalk J, Nguon C, Hien TT, Day N, White NJ, Dondorp A, Nosten F. The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. Malar J. 2015 Sep 30;14:381. doi: 10.1186/s12936-015-0906-x.</citation>
    <PMID>26424000</PMID>
  </reference>
  <reference>
    <citation>Imwong M, Hanchana S, Malleret B, Rénia L, Day NP, Dondorp A, Nosten F, Snounou G, White NJ. High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. J Clin Microbiol. 2014 Sep;52(9):3303-9. doi: 10.1128/JCM.01057-14. Epub 2014 Jul 2.</citation>
    <PMID>24989601</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Forest ranger</keyword>
  <keyword>P.falciparum</keyword>
  <keyword>P.vivax</keyword>
  <keyword>Dihydroartemisinine-piperaquine (DP)</keyword>
  <keyword>Primaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual participant data will be made available to researcher and public as a supporting material via open access journal and/or upon request by qualified research groups.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

